[go: up one dir, main page]

HK1250958A1 - 用於治療癌症的組合物和方法 - Google Patents

用於治療癌症的組合物和方法

Info

Publication number
HK1250958A1
HK1250958A1 HK18110314.8A HK18110314A HK1250958A1 HK 1250958 A1 HK1250958 A1 HK 1250958A1 HK 18110314 A HK18110314 A HK 18110314A HK 1250958 A1 HK1250958 A1 HK 1250958A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
treating cancer
cancer
treating
Prior art date
Application number
HK18110314.8A
Other languages
English (en)
Inventor
Vlerken-Ysla Lilian Emilia Van
Elaine Marie Hurt
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of HK1250958A1 publication Critical patent/HK1250958A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
HK18110314.8A 2015-07-14 2018-08-13 用於治療癌症的組合物和方法 HK1250958A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562192204P 2015-07-14 2015-07-14
PCT/US2016/042100 WO2017011559A1 (en) 2015-07-14 2016-07-13 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
HK1250958A1 true HK1250958A1 (zh) 2019-01-18

Family

ID=57757548

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110314.8A HK1250958A1 (zh) 2015-07-14 2018-08-13 用於治療癌症的組合物和方法

Country Status (13)

Country Link
US (3) US20180237515A1 (zh)
EP (1) EP3322484B1 (zh)
JP (1) JP6895946B2 (zh)
KR (1) KR20180027568A (zh)
CN (1) CN107847764B (zh)
AU (2) AU2016291803A1 (zh)
CA (1) CA2992091A1 (zh)
ES (1) ES2871252T3 (zh)
HK (1) HK1250958A1 (zh)
IL (1) IL256763A (zh)
RU (1) RU2729396C2 (zh)
SG (1) SG10201912086QA (zh)
WO (1) WO2017011559A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3206126A1 (en) 2021-01-15 2022-07-21 Universite De Fribourg Biomarkers for breast cancer detection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2591771A1 (en) 2002-04-11 2013-05-15 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
US7258873B2 (en) 2002-04-11 2007-08-21 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
JP4680601B2 (ja) 2002-12-17 2011-05-11 メディミューン・エルエルシー 生物活性材料の高圧噴霧乾燥
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2008282218A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
WO2009156994A1 (en) * 2008-06-24 2009-12-30 Hadasit Medical Research Services And Development Ltd. Ccl20-specific antibodies for cancer therapy
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
KR100950195B1 (ko) * 2009-03-20 2010-03-29 서울대학교산학협력단 Znf281을 발현하는 제대혈 유래 만능 줄기세포의 분리방법
ES2604108T3 (es) * 2010-06-28 2017-03-03 Universitätsklinikum Freiburg Bloqueo de la señalización de la CCL18 a través del CCR6 como opción terapéutica en las enfermedades fibróticas y el cáncer
TWI589587B (zh) * 2010-11-19 2017-07-01 衛材R&D企管股份有限公司 中和性抗-ccl20抗體
US9689040B2 (en) * 2011-03-04 2017-06-27 Children's Medical Center Corporation Selective inhibitors of tumor-initiating cells
EP2729488A4 (en) 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
US9057055B2 (en) * 2012-12-05 2015-06-16 The Royal Institution For The Advancement Of Learning/Mcgill University Method of obtaining circulating cancer cell populations

Also Published As

Publication number Publication date
US20180237515A1 (en) 2018-08-23
RU2018105217A3 (zh) 2020-01-27
EP3322484A1 (en) 2018-05-23
AU2019229394A1 (en) 2019-10-03
WO2017011559A1 (en) 2017-01-19
RU2018105217A (ru) 2019-08-14
JP6895946B2 (ja) 2021-06-30
SG10201912086QA (en) 2020-02-27
CN107847764A (zh) 2018-03-27
EP3322484B1 (en) 2021-03-24
AU2016291803A1 (en) 2018-02-22
KR20180027568A (ko) 2018-03-14
US20200102382A1 (en) 2020-04-02
US20210380673A1 (en) 2021-12-09
WO2017011559A8 (en) 2018-02-01
CA2992091A1 (en) 2017-01-19
CN107847764B (zh) 2022-07-05
IL256763A (en) 2018-03-29
EP3322484A4 (en) 2019-03-06
RU2729396C2 (ru) 2020-08-06
JP2018520177A (ja) 2018-07-26
ES2871252T3 (es) 2021-10-28

Similar Documents

Publication Publication Date Title
IL304820A (en) Preparations and methods for the treatment of cancer
IL267247B (en) Compositions and methods for treating cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
AU2022231657A1 (en) Compositions and Methods for Treating Cancer
IL258955A (en) Preparations and methods for the treatment of cancer
PT3377516T (pt) Composição para o tratamento do cancro
HK1251862A1 (zh) 治療癌症的方法和組合物
IL269150B2 (en) Cancer treatment preparations and methods
IL255261A0 (en) Cancer treatment methods
SG11201700079VA (en) Combination therapy compositions and methods for treating cancers
PT3200815T (pt) Métodos e composições para o tratamento de cancro
IL269157A (en) Preparations and methods for the treatment of cancer
IL256523A (en) Compositions and methods for treating cancer
HK1250944A1 (zh) 用於治療癌症的方法
HK1250942A1 (zh) 用於治療癌症的方法
IL255638A (en) Compositions and methods for treating cancer
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
EP3154544A4 (en) Compositions and methods for treating cancers
HK1250943A1 (zh) 用於治療癌症的方法
IL272782A (en) Preparations and methods for the treatment of cancer
ZA201802268B (en) Methods and compositions for preventing or treating cancer
EP3268028A4 (en) Compositions and methods for treating cancer
HK1250958A1 (zh) 用於治療癌症的組合物和方法
EP3160591A4 (en) Compositions and methods for treating cancer
GB201521083D0 (en) Compositions for treatment and methods thereof